Infliximab for inpatient psoriasis management - Is there a role?

Journal of Dermatological Treatment

Volumn 16, Issue 5-6, 2005, Pages 314-318

  Nelson, Andrew A ^a   Pearce, Daniel J ^b   Fleischer Jr , Alan B ^b   Balkrishnan, Rajesh ^c   Feldman, Steven R ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Biologic; Cost; Infliximab; Inpatient; Psoriasis treatment

Indexed keywords

INFLIXIMAB;

ARTICLE; COMPARATIVE STUDY; DATA BASE; DRUG EFFICACY; HEALTH CARE ORGANIZATION; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICARE; PRIORITY JOURNAL; PSORIASIS; REIMBURSEMENT; TIME SERIES ANALYSIS;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HOSPITAL CHARGES; HOSPITALIZATION; HUMANS; PRESCRIPTION FEES; PSORIASIS;

EID: 31644449205     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630500335951     Document Type: Article

References (17)

1. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80:430-4.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1): 401-7.
3. Goeckerman WH. Treatment of psoriasis. Northwest Med. 1925;24:229-31.
4. Goeckerman WH. Treatment of psoriasis: continued observations on the use of crude coal tar and ultraviolet light. Arch Dermatol Syphil. 1931;24:446-50.
5. Squire B. Chrysophanic acid ointment. Pharm J Trans. 1876;36:489-90.
6. Squire B. Treatment of psoriasis by an ointment of chrysophanic acid. Br Med J. 1876;2:819-20.
7. Stern RS; PUVA Follow-up Study. Inpatient hospital care for psoriasis: a vanishing practice in the United States. J Am Acad Dermatol. 2003;49:445-50.
8. Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003;4:1525-33.
9. Vensel E, Hilley T, Trent J, Taylor JR, Kirsner RS, Kerdel FA, et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol. 2000;43(5 Pt 1): 858-60.
10. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
11. Rongioletti F, Borenstein M, Kirsner R, Kerdel F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatol Treat. 2003;14:222-5.
12. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol. 2002;138:644-8.
13. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol. 2002;41:449-52.
14. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073-80.
15. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
16. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-27.
17. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-24.